Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dovitinib lactate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 36 for your search:
Start Over
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2105, NCT00303251
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2010-535, NCT01484041
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2201, 2008-005870-11, NCT00790426
TKI258 in Castrate Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: 2008-0510, NCI-2011-01106, NCT00831792
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2204, 2009-012417-22, NCT01058434
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2208, NCT01232296
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0650, NCI-2011-00305, NCT01266070
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2211, 2011-000266-35, NCT01379534
Dovitinib in Adenoid Cystic Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: H-1012-047-344, NCT01417143
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: CTKI258AKR01T, NCT01440959
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258AIC02, 2011-001725-24, NCT01478373
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SOGUG2011-03, 2011-002873-47, NCT01514526
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 15627, NCT01524692
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A1201, NCT01576380
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCDCC#231, CTKI258AUS21T, NCT01676714
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OCOG-2012-DOVE, NCT01678105
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GU12-157, NCT01732107
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE4312, NCI-2012-02284, NCT01753713
Dovitinib in Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 23811, NCT01635907
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CTKI258AAU02T, ACTRN12612000140853, NCT01791387
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258AUS26, NCT01831726
Maintenance Dovitinib for Colorectal and Pancreas Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CTK1258AUS16T, Pro063, NCT01888965
An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 to 90
Sponsor: Other
Protocol IDs: 4-2012-0405, NCT01964144
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0086, NCI-2014-00887, NCT01994590
Start Over